How Can I buy Suboxone Online | Forum

Suboxoneis a prescription opioid medicine used to block the effects of opioid medication, including pain relief, which can lead to opioid abuse. Suboxone may be used alone or with other medications.

Suboxone belongs to a class of drugs called Opioid Antagonists, Analgesics, Opioid Partial Agonist.

It is not known if Suboxone is safe and effective in children.

Suboxone may cause serious side effects including:

• weak or shallow breathing,

• breathing that stops during sleep,

• confusion,

• loss of coordination,

• extreme weakness,

• blurred vision,

• slurred speech,

• upper stomach pain,

• loss of appetite,

• dark urine,

• clay-colored stools,

• yellowing of the skin or eyes (jaundice),

• nausea,

• dizziness,

• worsening tiredness or weakness,

• shivering,

• goose bumps,

• increased sweating,

• feeling hot or cold,

• runny nose,

• watery eyes,

• diarrhea, and

• muscle pain

Get medical help right away, if you have any of the symptoms listed above.

The most common side effects of Suboxoneinclude:

• dizziness,

• drowsiness,

• blurred vision,

• feeling drunk,

• trouble concentrating,

• withdrawal symptoms,

• tongue pain,

• redness or numbness inside your mouth,

• nausea,

• vomiting,

• constipation,

• headache,

• back pain,

• fast or pounding heartbeats,

• increased sweating, and

• sleep problems (insomnia)

Tell the doctor if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of Suboxone. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SUBOXONEsublingual tablet is an uncoated hexagonal orange tablet, debossed with an alphanumeric word identifying the product and strength. It contains buprenorphine HCl, a partial agonist at the mu-opioid receptor, and naloxone HCl dihydrate, an opioid receptor antagonist, at a ratio of 4:1 (ratio of free bases). It is intended for sublingual administration and is available in two dosage strengths, 2 mg buprenorphine with 0.5 mg naloxone and 8 mg buprenorphine with 2 mg naloxone. Each sublingual tablet also contains lactose, mannitol, cornstarch, povidone K30, citric acid, sodium citrate, FD&C Yellow No.6 color, magnesium stearate, acesulfame K sweetener and a lemon / lime flavor.

SUBOXONE sublingual film is indicated for treatment of opioid dependence. SUBOXONE sublingual film should be used as part of a complete treatment plan that includes counseling and psychosocial support.

Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to healthcare providers who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription.

SUBOXONE sublingual film is administered sublingually or buccally as a single daily dose.

Medication should be prescribed in consideration of the frequency of visits. Provision of multiple refills is not advised early in treatment or without appropriate patient follow-up visits.

Prior to induction, consideration should be given to the type of opioid dependence (i.e., long-or short-acting opioid products), the time since last opioid use, and the degree or level of opioid dependence.

Patients dependent on heroin or other short-acting opioid products may be inducted with either SUBOXONE sublingual film or with sublingual buprenorphine monotherapy. At treatment initiation, the first dose of SUBOXONE sublingual film should be administered when objective signs of moderate opioid withdrawal appear, not less than six hours after the patient last used opioids.

On Day 1, an induction dosage of up to 8 mg/2 mg SUBOXONE sublingual film is recommended. Clinicians should start with an initial dose of 2 mg/0.5 mg or 4 mg/1 mg buprenorphine/naloxone and may titrate upwards in 2 or 4 mg increments of buprenorphine, at approximately 2-hour intervals, under supervision, to 8 mg/2 mg buprenorphine/naloxone based on the control of acute withdrawal symptoms.

On Day 2, a single daily dose of up to 16 mg/4 mg SUBOXONE sublingual film is recommended.

Because the exposure to naloxone is somewhat higher after buccal than after sublingual administration, it is recommended that the sublingual site of administration be used during induction to minimize exposure to naloxone, to reduce the risk of precipitated withdrawal.